Replicate Bioscience is extending its low-dose self-replicating RNA platform into tuberculosis, but immunological complexity, late-stage competition and global affordability create a demanding development path.
Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.
Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.
Forlong Biotechnology brings FL115 to ASCO 2026 with first-in-human solid tumor data. Read why the IL-15 story could matter beyond the poster.